# Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer

> **NCT00095277** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 220 (—)

## Conditions studied

- Anemia

## Interventions

- **DRUG:** Darbepoetin Alfa

## Key facts

- **NCT ID:** NCT00095277
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 220 (—)
- **Last updated:** 2009-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00095277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00095277, "Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00095277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*